US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety of the Biologic Lung Volume Reduction System (BLVR) for patients with advanced emphysema.

Clinical Trial Description

Emphysema is a progressive, debilitating disease that affects nearly 3 million people in the United States or roughly one percent of the US population. The disease is characterized by destruction of lung tissue as a result of inflammation caused by exposure to noxious inhaled agents for extended periods. The most common cause of this condition is cigarette smoking, although genetic and occupational causes account for up to 10% of cases. Despite aggressive public health initiatives aimed at discouraging the use of cigarettes, smoking-related lung diseases remain a significant cause of disability and death in the United States. Currently there are 46 million smokers in the US. Due to the number of current and new smokers, emphysema is expected to remain a leading cause of morbidity and mortality in the United States for years to come.

Aeris has developed a novel bronchoscopic system for achieving the benefits of lung volume reduction without surgery. The Biologic Lung Volume Reduction (BLVR) System, a new investigational therapy for emphysema, is intended to reduce lung volume over a period of weeks by collapsing and promoting the remodeling of diseased areas of the lung. The resulting reduction in lung volume is intended to restore a more normal physiological relationship between lung and chest wall, improve breathing and exercise capacity and alleviate symptoms of chronic dyspnea. This study will evaluate the safety of the BLVR System in patients with advanced emphysema. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00347659
Study type	Interventional
Source	Aeris Therapeutics
Contact
Status	Completed
Phase	Phase 1
Start date	June 2006
Completion date	September 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00995852` - Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study	Phase 2/Phase 3
Completed	`NCT01860898` - A Phase I Study of iPS Cell Generation From Patients With COPD	N/A
Completed	`NCT00123422` - Innovation in Pulmonary Rehabilitation	N/A
Recruiting	`NCT02879331` - Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils	N/A
Completed	`NCT01507415` - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?	N/A
Completed	`NCT01051258` - AeriSeal System for Lung Volume Reduction	Phase 1/Phase 2
Completed	`NCT00680056` - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients	Phase 4
Completed	`NCT01872624` - Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema	N/A
Completed	`NCT01110252` - Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease	N/A
Completed	`NCT00517998` - Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study	Phase 1
Terminated	`NCT00205920` - Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation	Phase 2
Withdrawn	`NCT01849159` - Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema	Phase 1/Phase 2
Completed	`NCT01869205` - The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients	Phase 3
Terminated	`NCT01320566` - A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema	Phase 2/Phase 3
Completed	`NCT00683722` - PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Active, not recruiting	`NCT04465461` - Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion	N/A
Completed	`NCT04012359` - Description of Bullous Emphysema Using Lung Ultrasound and Comparison to the Characteristics of Pneumothorax
Recruiting	`NCT04918706` - Allogeneic MSC Treatment for Pulmonary Emphysema	Phase 2
Terminated	`NCT01449292` - Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)	Phase 3
Recruiting	`NCT02827721` - Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)